Dr Elimova talks to ecancer at ESMO 2024 about data she presented from an ongoing phase 2 trial looking at zanidatamab plus chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).
The data suggest that the regimen continues to show promising antitumor activity with encouraging overall survival and a manageable safety profile as a first-line therapy for mGEA.
Негізгі бет Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma
Пікірлер